Group 1 - The core viewpoint of the articles highlights that the company, Jinxin Reproductive Medicine (01951), has shown resilience in its IVF cycle numbers, with a projected improvement in Q4 2025 compared to Q3 2025, despite an 8.0% decline in H1 2025 compared to H1 2024 [1] - The overall decline in IVF cycles has narrowed from -5.2% in the first three quarters of 2024 to -1.4% for the entire year of 2025, indicating a recovery trend [1] - The flagship hospital in Chengdu has seen a turnaround, with IVF cycles growing by 1.3% in 2025 compared to a decline of -1.9% in the first three quarters of 2025 [1] Group 2 - Looking ahead to 2026 and beyond, the company plans to enhance clinical treatment outcomes, patient care quality, and service supply levels, while accelerating the upgrade of core reproductive medical technologies [2] - The company aims to strengthen its market position in Chengdu and expand its capacity in the Greater Bay Area following the relocation of new facilities, while also addressing overseas policy changes to tap into international market growth potential [2] - The company intends to leverage national fertility support policies and industry development opportunities to solidify its competitiveness and provide high-quality medical services, ultimately creating long-term stable value for shareholders [2]
锦欣生殖2025年IVF取卵周期数整体降幅进一步收窄至-1.4%